文献速递临床试验与 GCP基础与转化研究

mRNA狂犬病疫苗在健康成人中的安全性和免疫原性:一项开放标签、非随机、前瞻性、首次人体1期临床试验

Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial.
PubMed 文献 · Lancet · 2017-07-25

这项在德国慕尼黑单中心开展的开放标签、非随机、前瞻性1期试验,纳入101名18-40岁无狂犬病疫苗接种史的健康成人,评估编码狂犬病毒糖蛋白的mRNA疫苗CV7201经针筒或三种无针装置皮内或肌内接种的安全性和免疫原性。结果显示无针装置接种可诱导部分受试者产生≥0.5 IU/mL的中和抗体,而针筒注射无效;疫苗总体安全,耐受性合理。

要点

  • 无针装置皮内或肌内接种CV7201可在部分受试者中诱导≥0.5 IU/mL的狂犬病毒中和抗体。
  • 针筒皮内或肌内注射无效,仅1名接受320 μg皮内接种者出现可检测的免疫反应。
  • 接种后7天内 solicited 注射部位反应和全身不良事件常见,包括10例3级事件。

核心结论

  • 首次在人体中证明,预防性mRNA候选疫苗经无针装置接种可诱导可加强的功能性抗病毒抗体,而针筒注射无效。
  • 疫苗总体安全,耐受性合理。

研究设计与样本

  • 开放标签、非随机、前瞻性、首次人体1期临床试验,在德国慕尼黑一个中心开展。
  • 纳入101名18-40岁无狂犬病疫苗接种史的健康男性和女性志愿者,序贯入组。
  • 受试者通过针筒或三种无针装置之一接受皮内或肌内注射三剂CV7201,后续队列递增剂量,一个队列在1年后接受加强针。
  • 主要终点为安全性和耐受性;次要终点为确定引发≥0.5 IU/mL(WHO规定保护性抗体滴度)狂犬病毒中和抗体的最低CV7201剂量。
  • 研究注册号ClinicalTrials.gov NCT02241135。

主要发现

  • 2013年10月21日至2016年1月11日期间,入组并接种101名参与者,共接受306剂mRNA(80-640 μg),其中针筒皮内18剂、针筒肌内24剂、无针装置皮内46剂、无针装置肌内13剂。
  • 接种后7天内,64名皮内接种者中60名(94%)和37名肌内接种者中36名(97%)报告 solicited 注射部位反应;64名皮内接种者中50名(78%)和37名肌内接种者中29名(78%)报告 solicited 全身不良事件,包括10例3级事件。
  • 一例意外的、可能相关的严重不良反应发生于640 μg肌内剂量接种后7天,无后遗症恢复。
  • 无针装置皮内或肌内注射在80 μg或160 μg皮内剂量组45名参与者中32名(71%)、200 μg或400 μg肌内剂量组13名参与者中6名(46%)诱导≥0.5 IU/mL的中和抗体滴度。
  • 1年后,接受80 μg无针皮内加强针的14名参与者中8名(57%)达到≥0.5 IU/mL滴度;而针筒皮内或肌内注射无效,仅1名接受320 μg皮内接种者出现可检测的免疫反应。

关键数值与推荐

  • WHO规定的保护性抗体滴度为0.5 IU/mL。
  • 无针皮内80 μg或160 μg组:32/45(71%)达到≥0.5 IU/mL。
  • 无针肌内200 μg或400 μg组:6/13(46%)达到≥0.5 IU/mL。
  • 加强针80 μg无针皮内后1年:8/14(57%)达到≥0.5 IU/mL。
  • 针筒注射组仅1名(320 μg皮内)出现可检测免疫反应。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vaccines based on mRNA coding for antigens have been shown to be safe and immunogenic in preclinical models. We aimed to report results of the first-in-human proof-of-concept clinical trial in healthy adults of a prophylactic mRNA-based vaccine encoding rabies virus glycoprotein (CV7201). METHODS: We did an open-label, uncontrolled, prospective, phase 1 clinical trial at one centre in Munich, Germany. Healthy male and female volunteers (aged 18-40 years) with no history of rabies vaccination were sequentially enrolled. They received three doses of CV7201 intradermally or intramuscularly by needle-syringe or one of three needle-free devices. Escalating doses were given to subsequent cohorts, and one cohort received a booster dose after 1 year. The primary endpoint was safety and tolerability. The secondary endpoint was to determine the lowest dose of CV7201 to elicit rabies virus neutralising titres equal to or greater than the WHO-specified protective antibody titre of 0·5 IU/mL. The study is continuing for long-term safety and immunogenicity follow-up. This trial is registered with ClinicalTrials.gov, number NCT02241135. FINDINGS: Between Oct 21, 2013, and Jan 11, 2016, we enrolled and vaccinated 101 participants with 306 doses of mRNA (80-640 μg) by needle-syringe (18 intradermally and 24 intramuscularly) or needle-free devices (46 intradermally and 13 intramuscularly). In the 7 days post vaccination, 60 (94%) of 64 intradermally vaccinated participants and 36 (97%) of 37 intramuscularly vaccinated participants reported solicited injection site reactions, and 50 (78%) of 64 intradermally vaccinated participants and 29 (78%) of 37 intramuscularly vaccinated participants reported solicited systemic adverse events, including ten grade 3 events. One unexpected, possibly related, serious adverse reaction that occurred 7 days after a 640 μg intramuscular dose resolved without sequelae. mRNA vaccination by needle-free intradermal or intramuscular device injection induced virus neutralising antibody titres of 0·5 IU/mL or more across dose levels and schedules in 32 (71%) of 45 participants given 80 μg or 160 μg CV7201 doses intradermally and six (46%) of 13 participants given 200 μg or 400 μg CV7201 doses intramuscularly. 1 year later, eight (57%) of 14 participants boosted with an 80 μg needle-free intradermal dose of CV7201 achieved titres of 0·5 IU/mL or more. Conversely, intradermal or intramuscular needle-syringe injection was ineffective, with only one participant (who received 320 μg intradermally) showing a detectable immune response. INTERPRETATION: This first-ever demonstration in human beings shows that a prophylactic mRNA-based candidate vaccine can induce boostable functional antibodies against a viral antigen when administered with a needle-free device, although not when injected by a needle-syringe. The vaccine was generally safe with a reasonable tolerability profile. FUNDING: CureVac AG.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Alberer M, Gnad-Vogt U, Hong HS, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet. 2017. PMID: 28754494. doi:10.1016/S0140-6736(17)31665-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。